Ghiaccio, Valentina
Chappell, Maxwell
Rivella, Stefano
Breda, Laura
Funding for this research was provided by:
FP7-HEALTH-2012-INNOVATION (THALAssaemia MOdular Stratification System for personalized therapy of ?-thalassemia)
Foundation for the National Institutes of Health (NIDDK-R01DK090554, NIDDK-R01DK095112)
Article History
First Online: 30 January 2019
Compliance with Ethical Standards
:
: LB, VG and MC declare no conflict of interest. SR is a consultant for Ionis Pharmaceuticals.
: This review was made possible through the collaboration of LB and SR in the THALAssaemia MOdular Stratification System for personalized therapy of β-thalassemia (THALAMOSS), European Community: FP7-HEALTH-2012-INNOVATION. This work is supported by grants from the National Institutes of Health (NIDDK-R01DK090554 and NIDDK-R01DK095112 to S.R.). The authors gratefully acknowledge the generous support by the Jean, Schejola and Di Gaetano families and the Children’s Hospital of Philadelphia Foundation.